Ecstasy (MDMA) and oral health

British Dental Journal

Volumn 204, Issue 2, 2008, Pages 77-81

  Brand, H S ^a   Dun, S N ^b   Nieuw Amerongen, A V ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Section of Oral Biochemistry

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; PSYCHEDELIC AGENT;

ADDICTION; ADULT; ANIMAL; ARTICLE; BRUXISM; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DENTAL CARE; HUMAN; MOUTH ULCER; SALIVA; TOOTH DISEASE; XEROSTOMIA;

ADULT; ANIMALS; BRUXISM; DENTAL CARE FOR CHRONICALLY ILL; HALLUCINOGENS; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; ORAL ULCER; SALIVA; SUBSTANCE-RELATED DISORDERS; TOOTH ABRASION; TOOTH EROSION; XEROSTOMIA;

EID: 38749118639     PISSN: 00070610     EISSN: 17417503     Source Type: Journal    
DOI: 10.1038/bdj.2008.4     Document Type: Article

References (46)

1. Cohen R S. Subjective reports on the effects of the MDMA ('ecstasy') experience in humans. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 1137-1145.
2. Zervogiannis F H, Wiechers E, Bester G. The 'E' In rave: a profile of young ecstasy (MDMA) users.S Afr J Psychol 2003; 33: 162-169.
3. McDowell D M, Kleber H B. MDMA: its history and pharmacology. Psychiatr Ann 1994; 24: 127-130.
4. Cole J C, Sumnall H R. Altered states: the clinical effects of ecstasy. Pharmacol Ther 2003; 98: 35-38.
5. Hall A P, Henry J A. Acute toxic effects of 'ecstasy' (MDMA) and related compounds; overview of pathophysiology and clinical management. Br J Anaesth 2006; 96: 678-685.
6. Baggott M, Heifets B, Jones R T et al. Chemical analysis of ecstasy J Am Med Assoc 2000; 284: 2190.
7. Tossmann P, Boldt S, Tensil M D. The use of drugs within the techno party scene in European metropolitan cities. Eur Addict Res 2001; 7: 2-23.
8. United Nations Office on Drugs and Crime. World drug report 2007. pp 161-165.
9. Newbury-Birch D, Lowry R J, Kamali F. The changing patterns of drinking, illicit drug use, stress, anxiety and depression in dental students in a UK dental school: a longitudinal study. Br Dent J 2002; 192: 646-649.
10. Underwood B, Fox K. A survey of alcohol and drug use among UK based dental undergraduates. Br Denf J 2000; 189: 314-317.
11. Underwood B, Fox K, Nixon PJ. Alcohol and drug use among vocational dental practitioners. Br Dent J 2003; 195: 265-268.
12. Torre R de la, Farré M, Navarro M et al. Clinical pharmacokinetics of amfetamine and related substances, monitoring in conventional and non-conventional matrices. Clin Pharmacokinet 2004; 43: 157-185.
13. Navarro M, Pichini S, Farré M et al. Usefulness of saliva for measurement of 3,4-methylenedi-oxymethamphetamine and its metabolites: correlation with plasma drug concentrations and effect of salivary pH. Clin Chem 2001; 47: 1788-1795.
14. Vollenweider F X, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA ('ecstasy') in MDMA-naive healthy volunteers. Neuropsychopharmacology 1998; 19: 241-250.
15. Schifano F, Oyefeso A, Carkery J et al. Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales. Hum Psychopharmacol 2003; 18: 519-524.
16. Colado M I, Williams J L, Green A R. The hyperthermic and neurotoxic effect of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the dark agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol 1995; 115: 1281-1289.
17. Screaton G R, Cairns H S, Sarner M et al. Hyperpyrexia and rabdomyolysis after MDMA ('ecstasy') abuse. Lancet 1992; 339: 677-678.
18. Kalant H. The pharmacology and toxicology of 'ecstasy'(MDMA) and related drugs. Con Med Assoc J 2001; 165: 917-928.
19. Gaffin S L, Gardner J W, Flinn S D. Cooling methods for heatstroke victims. Ann Intern Med 2000; 132: 678.
20. Halperin M L, Goldstein M B. Sodium and water. In Halperin M L, Goldstein M B (eds). Fluid, electrolyte, and acid-base physiology, pp 227-329. Philadelphia: WB Saunders Company, 1999.
21. McCann U D, Szabo Z, Scheffel U, Dannals R F, Ricaurte G A. Positron emission tomographic evidence of toxic effect of MDMA (ecstasy) on brain serotonin neurons In human beings. Lancet 1998; 352: 1433-1437.
22. Redfearn P J, Agrawal N, Mair L H. An association between the regular use of 3,4 methylenedloxy-methamphetamine (ecstasy) and excessive wear of the teeth. Addiction 1998; 93: 745-748.
23. McGrath C, Chan B. Oral health sensations associated with illicit drug abuse. Br Dent J 2005; 198: 159-162.
24. Milosevic A, Agrawal N, Redfearn P J, Mair L H. The occurrence of toothwear in users of ecstasy (3,4 MethyleneDioxyMethAmphetamine). Community Dent Oral Epidemiol 1999; 27: 283-287.
25. Nixon PJ, Youngson CC, BeeseA. Tooth surface loss: does recreational drug use contribute? Clin Oral Investig 2002; 6: 128-130.
26. Verheijden S L, Henry J A, Curran H V. Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users. Hum Psychopharmacol 2003; 18: 507-517.
27. Liechti M E, Gamma A, Vollenweider F X. Gender differences in the subjective effects of MDMA. Psychopharmacology2001; 154: 161-168.
28. Solowij N, Hall W, Lee N. Recreational MDMA use in Sydney; a profile of 'ecstasy' users and their experiences with the drug. Br J Addict 1992; 87: 1161-1172.
29. Harris D S, Baggott M, Mendelson J H, Mendelson J E, Jones R T. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) In humans. Psychopharmacolagy 2002; 162: 396-405.
30. Duxbury A J. Ecstasy - dental implications. Br Dent J 1993; 175: 38.
31. Murray M C, Wilson NHF. Ecstasy related tooth wear. Br Dent J 1998; 185:264.
32. Brazier W J, Dhariwal D K, Patton D W, Bishop K. Ecstasy related periodontitis and mucosal ulceration - a case report. Br Dent J 2003; 194: 197-199.
33. Arrue A, Gómez F M, Giralt M T. Effects of 3,4 methylenedioxymethamphetamine (ecstasy) on the jaw-opening reflex and on the α-adrenoceptors which regulate this reflex in the anesthetized rat. Eur J Oral Sci 2004; 112: 127-133.
34. Doyon S. The many faces of ecstasy. Curr Opin Pediatr 2001; 13: 170-176.
35. Liester M B, Grob C S, Bravo G L, Walsh R N. Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J Nerv Ment Dis 1992; 180: 345-352.
36. Greer G, Tolbert R. Subjective reports of the effects of 3,4-methylenedioxymethamphetamine In a clinical setting. J Psychoactive Drugs 1986; 18: 319-327.
37. Parry J, Porter S, Scully C, Flint S. Mucosal lesions due to oral cocaine use. Br Dent J 1996; 180: 462-464.
38. Ahmed M, Islam S, Hoffmann G R. Widespread oral and oropharyngeal mucosal oedema Induced by ecstasy (MDM): a case for concern. Br J Oral Maxillofac Surg 2005; 45: 496-498.
39. Chinet L, Stephan P, Zobel F, Halfon O. Party drug use In techno nights: a field survey among Frenchspeaking Swiss attendees. Pharmacol Biochem Behav 2007; 86: 284-289.
40. Veerman E C I, van den Keijbus P A M, Vissink A, Nieuw Amerongen A V. Human glandular salivas: their separate collection and analysis. Eur J Oral Sci 1996; 104: 346-352.
41. Samyn N, Boeck G de, Wood M et al. Plasma, oral fluid and sweat wipe ecstasy concentrations In controlled and real life conditions. Forensic Scilnt 2002; 128: 90-97.
42. Pichini S, Navarro M, Farré M et al. On-site testing of 3,4-methylenedioxymethamphetamine (ecstasy) In saliva with drugwipe and drugread: a controlled study in recreational users. Clin Chem 2002; 48: 174-176.
43. Mancinelli R, Gentili S, Guiducci M S, Macchia T. Simple and reliable high-performance liquid chromatography fluorimetric procedure for the determination of amphetamine-derived designer drugs. J Chromatogr B Biomed Sci Appl 1999; 735: 243-253.
44. Mortier K A, Maudens K E, Lambert W E et al. Simultaneous, quantitative determination of opiates, amphetamines, cocaine and benzoylecgonine in oral fluid by liquid chromatography quadrupole-time-of-flight mass spectrometry. J Chromatogr B Biomed Sci Appl 2002; 779: 321-330.
45. Goodchild J H. Methamphetamine abuse and the impact on dental health. Dent Today 2007; 26: 124-131.
46. Birnbach D J. Anesthetic management of the drugabusing parturient: are you ready? J Clin Anesth 2003; 15: 325-327.